Gut Microbial Dysbiosis Is Associated With Profibrotic Factors in Liver Fibrosis Mice

Wan, Sizhe; Nie, Yuan; Zhang, Yue; Huang, Chia-Chi Flora; Zhu, Xuan

doi:10.3389/fcimb.2020.00018

Cited by 16 publications

(13 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considered a complex organ, the microbial community is required in the committed step through which food would be converted into small compounds and metabolites, thus modulating intestine structure, gut barrier integrity, inflammatory status, and host metabolism both directly and indirectly [ 4 ]. Since Hippocrates claimed that “all diseases begin in the gut” centuries ago, a great body of research has demonstrated the interplay between intestinal microbiota and diseases, including colorectal cancer [ 5 ], cerebral ischemia-reperfusion injury [ 6 ], liver fibrosis [ 7 ], and CVDs [ 8 ]. The gut microbiota accounts for 0.2–2.0 kg of the weight of an adult and approximately 50% of the dry weight of adult feces.…”

Section: Introductionmentioning

confidence: 99%

Implication of Gut Microbiota in Cardiovascular Diseases

Zhou

Cheng

Zhu

et al. 2020

Oxidative Medicine and Cellular Longevity

107

View full text Add to dashboard Cite

Emerging evidence has identified the association between gut microbiota and various diseases, including cardiovascular diseases (CVDs). Altered intestinal flora composition has been described in detail in CVDs, such as hypertension, atherosclerosis, myocardial infarction, heart failure, and arrhythmia. In contrast, the importance of fermentation metabolites, such as trimethylamine N-oxide (TMAO), short-chain fatty acids (SCFAs), and secondary bile acid (BA), has also been implicated in CVD development, prevention, treatment, and prognosis. The potential mechanisms are conventionally thought to involve immune regulation, host energy metabolism, and oxidative stress. However, numerous types of programmed cell death, including apoptosis, autophagy, pyroptosis, ferroptosis, and clockophagy, also serve as a key link in microbiome-host cross talk. In this review, we introduced and summarized the results from recent studies dealing with the relationship between gut microbiota and cardiac disorders, highlighting the role of programmed cell death. We hope to shed light on microbiota-targeted therapeutic strategies in CVD management.

show abstract

Section: Introductionmentioning

confidence: 99%

Implication of Gut Microbiota in Cardiovascular Diseases

Zhou

Cheng

Zhu

et al. 2020

Oxidative Medicine and Cellular Longevity

107

View full text Add to dashboard Cite

show abstract

“…While there is no established link between arthrofibrosis and the gut microbiome, other diseases resulting in fibrosis are associated with gut dysbiosis. Cystic fibrosis is associated with reduced gut microbial diversity and increased F/B ratio and inflammatory markers 87,88 and liver fibrosis and systemic scleroderma are associated with decreased diversity and abundance in the gut microbiome 89‐92 …”

Section: Discussionmentioning

confidence: 99%

“…Cystic fibrosis is associated with reduced gut microbial diversity and increased F/B ratio and inflammatory markers 87,88 and liver fibrosis and systemic scleroderma are associated with decreased diversity and abundance in the gut microbiome. [89][90][91][92] A second potential mechanism of communication between the implant microenvironment and the gut is the translocation of serum metal ions. We have shown in our model that elevated serum cobalt and titanium ions are associated with CoCr particle challenge.…”

mentioning

confidence: 99%

The gut microbiota may be a novel pathogenic mechanism in loosening of orthopedic implants in rats

Moran

Wilson

et al. 2020

The FASEB Journal

View full text Add to dashboard Cite

Particles released from implants cause inflammatory bone loss, which is a key factor in aseptic loosening, the most common reason for joint replacement failure. With the anticipated increased incidence of total joint replacement in the next decade, implant failure will continue to burden patients. The gut microbiome is increasingly recognized as an important factor in bone physiology, however, its role in implant loosening is currently unknown. We tested the hypothesis that implant loosening is associated with changes in the gut microbiota in a preclinical model. When the particle challenge caused local joint inflammation, decreased peri-implant bone volume, and decreased implant fixation, the gut microbiota was affected. When the particle challenge did not cause this triad of local effects, the gut microbiota was not affected. Our results suggest that cross-talk between these compartments is a previously unrecognized mechanism of failure following total joint replacement. K E Y W O R D S bone volume, gut microbiome, implant, implant fixation, orthopedics | 14303 MORAN et Al. Vehicle Yes No 12 10 LPS-PE Yes Yes (LPS-doped PE) 12 12 Total 61 Experiment 3 Naïve No No 12 10 Vehicle Yes No 12 10 CoCr Yes Yes (CoCr) 12 11

show abstract

“…Twenty female BALB/c mice (6–8 weeks, 18–22 g) were purchased from the Center of Comparative Medicine Centre of Yangzhou University (permit number: SCXK (SU) 2012-0004) and allowed to acclimatize for 3 days in the laboratory. A bacteria-infected mouse model was created by oral gavage with 200 μL of E. coli containing 1 × 10 7 CFU/mL into female BALB/c mice (n = 15) [ 43 ]. The healthy mice (n = 5), as a group, were not infected with E. coli .…”

Section: Methodsmentioning

confidence: 99%

Plasmon-Enhanced Antibacterial Activity of Chiral Gold Nanoparticles and In Vivo Therapeutic Effect

Wang

Zhang

et al. 2021

Nanomaterials

View full text Add to dashboard Cite

d-cysteine (d-cys) has been demonstrated to possess an extraordinary antibacterial activity because of its unique steric configuration. However, inefficient antibacterial properties seriously hinder its wide applications. Here, cysteine-functionalized gold nanoparticles (d-/l-Au NPs) were prepared by loading d-/l-cysteine on the surface of gold nanoparticles for the effective inhibition of Escherichia coli (E. coli) in vitro and in vivo, and the effects on the intestinal microflora in mice were explored during the treatment of E. coli infection in the gut. We found that the antibacterial activity of d-/l-Au NPs was more than 2–3 times higher than pure d-cysteine, l-cysteine and Au NPs. Compared with l-Au NPs, d-Au NPs showed the stronger antibacterial activity, which was related to its unique steric configuration. Chiral Au NPs showed stronger destructive effects on cell membrane compared to other groups, which further leads to the leakage of the cytoplasm and bacterial cell death. The in vivo antibacterial experiment illustrated that d-Au NPs displayed impressive antibacterial activity in the treatment of E. coli-infected mice comparable to kanamycin, whereas they could not affect the balance of intestinal microflora. This work is of great significance in the development of an effective chiral antibacterial agent.

show abstract

Gut Microbial Dysbiosis Is Associated With Profibrotic Factors in Liver Fibrosis Mice

Cited by 16 publications

References 38 publications

Implication of Gut Microbiota in Cardiovascular Diseases

Implication of Gut Microbiota in Cardiovascular Diseases

The gut microbiota may be a novel pathogenic mechanism in loosening of orthopedic implants in rats

Plasmon-Enhanced Antibacterial Activity of Chiral Gold Nanoparticles and In Vivo Therapeutic Effect

Contact Info

Product

Resources

About